PREOPANC-1

NCT01562353 📎

Regimen

Experimental
Neoadjuvant gemcitabine 1000 mg/m2 d1,8,15 q4w x 3 cycles combined with 36 Gy / 15 fx radiotherapy during cycle 2, then surgery, then 4 cycles adjuvant gemcitabine.
Control
Upfront surgery followed by 6 cycles adjuvant gemcitabine.

Population

Resectable or borderline resectable PDAC, ECOG 0-1, 16 Dutch centers, enrolled 2013-2017, long-term follow-up 2022.

Key finding

PREOPANC-1 long-term follow-up (2022) showed neoadjuvant gemcitabine-chemoradiation significantly improves OS vs upfront surgery in combined resectable + borderline PDAC, driven primarily by the borderline-resectable subgroup. R0 resection rate 71% vs 40% in favor of neoadjuvant arm.

Source: PMID 35084987

Timeline

    Guideline citations

    • NCCN PANCREATIC (p.71)